EDP Biotech Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • EDP Biotech's estimated annual revenue is currently $5.3M per year.(i)
  • EDP Biotech's estimated revenue per employee is $155,000

Employee Data

  • EDP Biotech has 34 Employees.(i)
  • EDP Biotech grew their employee count by 48% last year.

EDP Biotech's People

NameTitleEmail/Phone
1
Director Marketing & BrandingReveal Email/Phone
2
Finance and Operations DirectorReveal Email/Phone
3
Project ManagerReveal Email/Phone
4
Clinical Trial ManagerReveal Email/Phone
5
Clinical Trial ManagerReveal Email/Phone
6
Commercial Sales RepresentativeReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
N/A136N/AN/AN/A
Add Company

What Is EDP Biotech?

EDP Biotech Corporation is a privately held medical device company focused on the development and commercialization of blood based immunodiagnostic assays. During this unprecedented pandemic, EDP uses its blood-test technology and partnerships to bring FASTER COVID-19 diagnostic and serology testing as businesses and schools open across the Southeast US. Contact us for more details and to schedule your B2B consultation for testing services. EDP's first commercially focused oncology product, ColoPlexâ„¢, is a unique multiplex assay to be used in the early detection of colorectal cancer and pre-cancerous polyps.

keywords:N/A

N/A

Total Funding

34

Number of Employees

$5.3M

Revenue (est)

48%

Employee Growth %

N/A

Valuation

N/A

Accelerator

EDP Biotech News

2022-04-17 - Colorectal Cancer Market projected to reach US$ 22953.8 ...

Moreover, in September, 2017, EDP Biotech Corporation announced that it has received patent for U.S. Patent and Trademark Office for its...

2022-04-13 - Ascletis Announces 3CLpro Inhibitor ASC11 Demonstrated ...

... 16-fold of that of PBI-0451 and 7-fold of that of EDP-235. ... Ascletis is an innovative R&D driven biotech listed on the Hong Kong...

2022-04-13 - Ascletis' oral drug shows potential for Covid-19 treatment

... 16-fold and seven-fold to that of PBI-0451 and EDP-235, respectively, ... our discovery capability as a leading antiviral biotech.”.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.9M3410%N/A
#2
$7.3M346%N/A
#3
$6.8M3410%N/A
#4
$7.3M3410%N/A
#5
$7.9M3410%N/A